Notícias

U.S. lawmakers have opened a national security probe into Eli Lilly's (NYSE:LLY) clinical trial activities in China. The House Select Committee on China is seeking detailed information on trial oversight, data access, and ties to Chinese institutions. Lawmakers have set a July 17 deadline for Eli Lilly to respond with documents and explanations. Eli Lilly is a major global pharmaceutical company with a large portfolio across diabetes, obesity, oncology, immunology, and other therapeutic...

Cathie Wood Loads Up on AI Winners as She Cuts Roku and China Exposure

AMGN stands out compared to Biogen given its broader product portfolio, pipeline depth and steadier growth outlook despite patent and competition risks.

Eli Lilly and Altria stand out as defensive stock ideas as investors weigh a hawkish Fed, a pivotal jobs report and shifting market leadership.

Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.

Eli Lilly’s retatrutide has crossed the 30% weight loss benchmark in some patients. Where do GLP-1RAs go from here?

Millions of older Americans are on the cusp of more affordable access to popular weight-loss drugs when a major Medicare coverage expansion kicks in July 1.

Verzenios is a CDK4 and 6 inhibitor that has received approval in China for several indications related to breast cancer.

The healthcare giant is making waves, but its true value for investors lies in how little it moves with the market.

Medicare is launching a temporary program that will cover Novo’s Wegovy injection and tablets, as well as Lilly’s Zepbound KwikPen formulation and its Foundayo tablets.

Roche won FDA priority review for Enspryng in thyroid eye disease, with a decision date in October and phase III data backing the filing.

Eli Lilly transferred mainland China commercialization rights for Verzenio to Innovent Biologics.

A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck and AbbVie, were involved in clinical trials conducted in China that may have supported the country’s military capabilities, according to a...

The abbreviated week in the market could set the tone for the back half of 2026.

Seven pharma companies have been selected for the FDA PreCheck pilot – a framework intended to bolster the US drug supply chain.

LLY is expanding its revenue base beyond Mounjaro and Zepbound with new launches and label expansions that can strengthen long-term growth.

Innovent will take over importing, marketing, and distributing Verzenios in mainland China as generic competition looms

Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities are emerging far from Silicon Valley. Biotechnology has spent decades producing breakthrough medicines, yet drug development has remained painfully slow, often taking 10 to 15 years while roughly 90% of candidates never reach approval. AI is beginning to change that equation. By ... AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunity

Deal gives Innovent commercialization rights in mainland China.

The FDA estimates the PreCheck program could save participating companies up to 14 months by reviewing facilities while they are still under construction

June 30 (Reuters) - A bipartisan group of U. lawmakers has opened national security investigations into whether drugmakers Merck and AbbVie have been involved in clinical trials conducted in China that helped fuel the communist country's military capability, according ‌to letters seen by Reuters.

SpaceX recently completed a record IPO.

The weight loss tailwind isn't about to come to a halt.

Micron is now 1.9% of the benchmark index in terms of weight.

Given its significant hedge fund backing and attractive upside potential, NVIDIA Corporation (NASDAQ:NVDA) is one of the most promising robotics stocks. NVIDIA Corporation (NASDAQ:NVDA) is extending its physical AI ambitions on two fronts simultaneously, pushing deeper into industrial robotics safety while advancing its push into agentic life sciences. On June 23, 2026, NVIDIA Corporation (NASDAQ:NVDA) […]

The latest trading day saw Eli Lilly (LLY) settling at $1, representing a +1.81% change from its previous close.

AbbVie (ABBV) - a pharmaceutical company developing and selling specialized therapies - hit a 5-day winning streak, with cumulative gains over this period amounting to 17%. The company's market cap has surged by about $65 Bil over the last 5 days and currently stands at $448 Bil.

This pharma giant's recent run is grabbing headlines, but its long-term behavior tells a more interesting story about portfolio risk.

NVO and VKTX stocks offer contrasting opportunities in the fast-growing obesity market, with key differences in growth, risk and pipeline strength.

LLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, approvals and deal activity adding momentum.